An official website of the United States government
Home
Name
Lanreotide Acetate
Alternate Names
BIM 23104
BIM-23014
BIM23014
Somatuline
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
NSC Number
None
Primary Site
None
Histology
None
Remarks
This drug is usually considered ancillary treatment for neuroendocrine tumors as it relieves symptoms of neuroendocrine tumors but does not kill the tumor cells. HOWEVER, as of June 1, 2019, Somatuline Depot is the 1st and only FDA-approved treatment for adults both to slow the growth of gastrointestinal and pancreatic neuroendocrine tumors (GEP NETs) that have spread or cannot be removed by surgery. It also treats carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.
How to code: IF given to treat carcinoid syndrome, do not code. If give or stated to be prescribed to treat the tumor, then code as hormone
This drug is indicated for the treatment of acromegaly when the circulating levels of growth hormone remain abnormal after surgery and/or radiotherapy, but also used for the treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy. It may be used to treat pituitary tumors. If so, code as hormonal treatment.
How to code: IF given to treat carcinoid syndrome, do not code. If give or stated to be prescribed to treat the tumor, then code as hormone
This drug is indicated for the treatment of acromegaly when the circulating levels of growth hormone remain abnormal after surgery and/or radiotherapy, but also used for the treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy. It may be used to treat pituitary tumors. If so, code as hormonal treatment.
Coding
Please see remarks for additional information
